Update on development of interleukin-11.
This paper reviews the recent studies of interleukin-11 gene expression and regulation, receptor and signal transduction, pharmacologic effects, and preclinical and clinical studies. Interleukin-11 is expressed in cells of mesenchymal origin and gene expression can be modulated by several inflammatory cytokines and agonists. The signaling pathways involved in cytokine induction of interleukin-11 gene expression vary between cell types. In vitro and in vivo studies reveal that interleukin-11 displays a wide spectrum of bioactivities including responses in hematopoietic and nonhematopoietic cells. Preclinical studies in animal models suggest that interleukin-11 may be useful in acceleration of the recoveries of both hematopoietic cells and gastrointestinal mucosal cells after cytoablative therapies. Several clinical studies have demonstrated interleukin-11 to be well tolerated and suggest interleukin-11 is a promising cytokine to prevent both neutropenia and thrombocytopenia in patients with cancer who are receiving chemotherapy.